

Haematologica
HAEMATOL/2020/251900
Version 4

A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies

Hanny Al-Samkari, Aric D. Parnes, Katayoon Goodarzi, James I. Weitzman, Jean M. Connors, and David J. Kuter

Disclosures: UNIVERSAL DISCLOSURES: Al-Samkari: Consultancy (Agius, Dova, Moderna), Research Funding (Agius, Dova, Amgen). Parnes: Consultancy (Sunovion), Research Funding (Genentech/Hoffman LaRoche, Shire/Takeda), Scientific Advisory Board (Bayer, Shire/Takeda). Goodarzi: None. Weitzman: Consultancy (AbbVie). Connors: Scientific Advisory Board (Bristol-Myers Squibb, Portola), Consultancy (Bristol-Myers Squibb), Personal Fees (Bristol-Myers Squibb), Data Safety Monitoring Board (Unum Therapeutics). Kuter: Research funding (Protalex, Bristol-Myers Squibb, Rigel, Bioverativ, Agios, Syntimmune, Principia, Alnylam); Consultancy (ONO, Pfizer, 3SBios, Eisai, GlaxoSmithKline, Genzyme, Shire, Amgen, Shionogi, Rigel, Syntimmune, MedImmune, Novartis, Alexion, Bioverativ, Argenx, Zafgen, Fujifilm, Principia, Kyowa Kirin, Takeda, Platelet Disorders Support Group).

Contributions: H. Al-Samkari wrote the first draft of the manuscript and contributed to study design, data collection, data analysis, creation of tables and figures, critical revision of the manuscript, and final approval; A. D. Parnes contributed to romiplostim treatment pathway design, data collection, revision of the manuscript, and final approval; K. Goodarzi contributed to romiplostim treatment pathway design, revision of the manuscript, and final approval; J. I. Weitzman contributed to romiplostim treatment pathway design, revision of the manuscript, and final approval; J. M. Connors contributed to romiplostim treatment pathway design, revision of the manuscript, and final approval; D. J. Kuter contributed to romiplostim treatment pathway design, critical revision of the manuscript, and final approval.